What is the global market size of Urinary Tract Infection Testing Market?

Urinary Tract Infection Testing Market size was valued at USD 8.36 billion in 2021 and is poised to grow from USD 8.7 billion in 2022 to USD 12 billion by 2030, growing at a CAGR of 4.1% in the forecast period (2023-2030).

Urinary Tract Infection Testing Market Size, Share, Growth Analysis, By Infection Type(Urethritis, Cystitis, and Pyelonephritis), By Test Type(Urinalysis, Urine Cultures, Susceptibility Testing), By End-user(Hospitals, Diagnostic Laboratories, Research Institutes), By Test Kit(Home Test Kits, Laboratory Test Kits), By Region - Industry Forecast 2024-2031

Q: Who are the key vendors in the Global Urinary Tract Infection Testing Market?

The competitive landscape of the global urinary tract infection (UTI) market is characterized by a diverse array of players vying for market share. Established diagnostics and pharmaceutical companies, as well as innovative startups, contribute to the market's dynamism. These entities focus on developing advanced diagnostic tools, therapeutic solutions, and innovative treatment approaches to address the growing burden of UTIs. The competitive scenario is driven by a continuous quest for improved accuracy, faster results, and patient-friendly testing methods. 'QIAGEN (Germany)', 'Accelerate Diagnostics, Inc. (US)', 'Bio-Rad Laboratories, Inc. (US)', 'F. Hoffmann-La Roche Ltd. (Switzerland)', 'Danaher Corporation (US)', 'Siemens Healthcare GmbH (Germany)', 'Randox Laboratories Ltd. (UK)', 'Thermo Fisher Scientific, Inc. (US)', 'bioMérieux SA (France)', 'T2 Biosystems, Inc. (US)', 'Beckman Coulter, Inc. (US)', 'Becton, Dickinson and Company (US)', 'Sysmex Corporation (Japan)', 'Cepheid (US)', 'GenMark Diagnostics, Inc. (US)', 'Hologic, Inc. (US)', 'Ortho Clinical Diagnostics (US)', 'Luminex Corporation (US)', 'Bruker Corporation (US)', 'Trinity Biotech plc (Ireland)'.

Q: What is the key driver of Global Urinary Tract Infection Testing Market?

The global urinary tract infection (UTI) market is significantly influenced by the escalating prevalence of antibiotic resistant UTIs. The overuse and misuse of antibiotics have led to the emergence of bacteria that are resistant to traditional treatments, complicated UTI management. This pressing concern has driven the need for accurate diagnostic tools such as urine cultures and susceptibility testing, enabling healthcare providers to identify effective treatment options tailored to specific bacterial strains. Additionally, the urgency to contain antibiotic resistance has spurred investments in research and development for novel therapies, further shaping the market's dynamics toward innovative solutions that combat resistant UTIs while promoting prudent antibiotic use.

Q: What is the key market trend for Global Urinary Tract Infection Testing Market?

Rise of Point-of-Care (POC) Testing: In the global urinary tract infection (UTI) market, a prominent trend is the increasing adoption of Point-of-Care (POC) testing methods. POC tests offer rapid results and convenient on-site diagnostics, eliminating the need for centralized laboratory facilities and reducing turnaround times. This trend aligns with the demand for quick and accurate UTI diagnosis, especially in primary care settings. The integration of POC testing technologies empowers healthcare professionals to make timely treatment decisions, improve patient outcomes, and optimize resource allocation. As technology advancements continue to enhance the accuracy and efficiency of POC tests, their widespread implementation is reshaping the landscape of UTI diagnostics.

Q: Which region accounted for the largest share in Global Urinary Tract Infection Testing Market?

North America emerges as the dominating force in the global urinary tract infection (UTI) market. This is attributed to its well-established healthcare infrastructure, high prevalence of UTIs, and strong emphasis on research and development. Additionally, a heightened awareness about UTIs among the population and swift adoption of advanced diagnostic technologies further fuel market growth.

Report ID: SQMIG35D2169 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 116 | Figures: 77

Urinary Tract Infection Testing Market News

In January 2024, Vivoo, a wellness application offering personalized nourishment and way-of-life counseling utilizing at-home urine tests, presented its computerized Urinary Tract Infection (UTI) testing item at CES 2024.
In February 2024, Recce Pharmaceuticals Ltd, an organization fostering another kind of synthetic anti-infective drugs, reported its continuous work at the Murdoch Children’s Research Institute (MCRI) in its Anti-Infective Research (AIR) Unit. The organization intends to smooth out its preclinical projects and investigate new purposes for future clinical trials.
In February 2024, Recce Drugs Ltd., an organization having some expertise in another class of synthetic anti-infectives, uncovered the marking of a Memorandum of Understanding (MoU) with PT Etana Biotechnologies, a conspicuous Indonesian biomedical organization. The joint effort plans to facilitate the clinical advancement of Recce's anti-infective portfolio in Indonesia, tending to the pressing worldwide medical problem of antimicrobial resistance (AMR).

Urinary Tract Infection Testing Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Urinary Tract Infection Testing Market size was valued at USD 8.7 billion in 2022 and is poised to grow from USD 9.06 billion in 2023 to USD 12.49 billion by 2031, growing at a CAGR of 4.1% in the forecast period (2024- 2031).

The competitive landscape of the urinary tract infection (UTI) market is characterized by a diverse array of players vying for market share. Established diagnostics and pharmaceutical companies, as well as innovative startups, contribute to the market's dynamism. These entities focus on developing advanced diagnostic tools, therapeutic solutions, and innovative treatment approaches to address the growing burden of UTIs. The competitive scenario is driven by a continuous quest for improved accuracy, faster results, and patient-friendly testing methods. 'QIAGEN (Germany)', 'Accelerate Diagnostics, Inc. (US)', 'Bio-Rad Laboratories, Inc. (US)', 'F. Hoffmann-La Roche Ltd. (Switzerland)', 'Danaher Corporation (US)', 'Siemens Healthcare GmbH (Germany)', 'Randox Laboratories Ltd. (UK)', 'Thermo Fisher Scientific, Inc. (US)', 'bioMérieux SA (France)', 'T2 Biosystems, Inc. (US)', 'Beckman Coulter, Inc. (US)', 'Becton, Dickinson and Company (US)', 'Sysmex Corporation (Japan)', 'Cepheid (US)', 'GenMark Diagnostics, Inc. (US)', 'Hologic, Inc. (US)', 'Ortho Clinical Diagnostics (US)', 'Luminex Corporation (US)', 'Bruker Corporation (US)', 'Trinity Biotech plc (Ireland)'

The urinary tract infection (UTI) market is significantly influenced by the escalating prevalence of antibiotic resistant UTIs. The overuse and misuse of antibiotics have led to the emergence of bacteria that are resistant to traditional treatments, complicated UTI management. This pressing concern has driven the need for accurate diagnostic tools such as urine cultures and susceptibility testing, enabling healthcare providers to identify effective treatment options tailored to specific bacterial strains. Additionally, the urgency to contain antibiotic resistance has spurred investments in research and development for novel therapies, further shaping the market's dynamics toward innovative solutions that combat resistant UTIs while promoting prudent antibiotic use.

Rise of Point-of-Care (POC) Testing: In the urinary tract infection (UTI) market, a prominent trend is the increasing adoption of Point-of-Care (POC) testing methods. POC tests offer rapid results and convenient on-site diagnostics, eliminating the need for centralized laboratory facilities and reducing turnaround times. This trend aligns with the demand for quick and accurate UTI diagnosis, especially in primary care settings. The integration of POC testing technologies empowers healthcare professionals to make timely treatment decisions, improve patient outcomes, and optimize resource allocation. As technology advancements continue to enhance the accuracy and efficiency of POC tests, their widespread implementation is reshaping the landscape of UTI diagnostics.

North America emerges as the dominating force in the urinary tract infection (UTI) market. This is attributed to its well-established healthcare infrastructure, high prevalence of UTIs, and strong emphasis on research and development. Additionally, a heightened awareness about UTIs among the population and swift adoption of advanced diagnostic technologies further fuel market growth.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Urinary Tract Infection Testing Market News

Urinary Tract Infection Testing Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Urinary Tract Infection Testing Market?

Who are the key vendors in the Urinary Tract Infection Testing Market?

What is the key driver of Urinary Tract Infection Testing Market?

What is the key market trend for Urinary Tract Infection Testing Market?

Which region accounted for the largest share in Urinary Tract Infection Testing Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300